Rezolute, Inc.
RZLTNext catalyst
Phase 3
Get an email about RZLT's next catalysts
Track Rezolute (RZLT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
RZLT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.18 | FQ end Sep/2026 | Call: tbd
Phase 3
Rezolute announced interim Phase III data for its tumour HI treatment, driving positive stock movement. Topline results from the fully enrolled open-label study are expected in the second half of 2026.
SourceMarket Overview
Stock performance and key metrics
No drugs found in this phase.
Frequently asked questions
When is Rezolute, Inc.'s next FDA catalyst?→
Rezolute, Inc.'s (RZLT) next tracked catalyst is a Phase 3 readout expected Dec 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RZLT biotech catalysts?→
Add RZLT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Rezolute, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.